-
Featured Authors
-
Archives
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
New PhRMA Report: A Decade of Innovation in Rare Diseases
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released “A Decade of Innovation in Rare Diseases,” which highlights 10 years of progress in understanding rare diseases and drug development resulting in groundbreaking therapies. According to the report, more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development. The Read More >
Op-Ed: As I Lay Dying
Former staff writer for the LA Times Laurie Becklund shares her experience ‘climbing ladders and falling down chutes’ as a metastatic breast cancer patient in this powerful op-ed. Becklund died in February, but left behind insights on how to improve the care and treatment of life-threatening diseases based on her first-hand experience. Becklund advocates for the creation of a ‘new system of data collection and an open, online, broad-range database about patient histories.’ This information Read More >
FOX Business: BIO CEO Jim Greenwood Discusses Future of Medicine
BIO President and CEO Jim Greenwood appeared on Fox Business during the 17th Annual BIO CEO & Investor Conference in New York City to discuss the future of medicine. Against a backdrop of policy discussions focused on how to encourage and incentivize innovation, this week’s conference hosted a record number of partnering meetings, as Greenwood emphasizes in the interview. Greenwood goes on to point out that investors closely follow policy trends, and their interest in Read More >
BIO CEO & Investor Conference Kicks Off in NYC
The 17th Annual BIO CEO & Investor Conference opened today with a record number of partnering meetings and company presentations, in addition to key policy, business, and science panels highlighting the biotech issues of the day. During the Welcome & Opening Plenary session, BIO President & CEO Jim Greenwood spoke with Energy & Commerce Committee Chairman Fred Upton (R-MI) and Congresswoman Diana DeGette (D-CO) about the 21st Century Cures Initiative, a comprehensive effort to accelerate the discovery, Read More >
How Industry Rates Interactions with the FDA
Kicking off day one of the BIO CEO & Investor Conference in New York City, panelists in the ‘How Industry Rates Interactions with the FDA’ session brought attendees good news – communication with the FDA has improved overall. “The improvements we have seen in increased communications between FDA and sponsors is based on a continuous dialogue that has been established over the past several years in which BIO has been at the forefront,” said Jonathan Read More >
